A Study on the Treatment Strategy of NVG Secondary to PDR
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
With the increasing incidence of proliferative diabetic retinopathy (PDR), subsequent
neovascular glaucoma (NVG) has become one of the main causes of blindness in PDR patients,
and the intraocular pressure of PDR patients with NVG is often stubborn. For these patients,
not only is the effect of drugs in lowering intraocular pressure poor, but the results of
surgery are often unsatisfactory. Because of its poor prognosis, clinical research for better
strategy is of great significance in the current situation. At present, for such patients, a
combination of effective control of intraocular pressure and treatment of the primary disease
is often used. The purpose of this study was to investigate the clinical effects of
preoperative or intraoperative anti-vascular endothelial growth factor (VEGF) drug therapy
combined with pars plana vitrectomy (PPV), pan-retinal photocoagulation (PRP), and
pressure-reducing valve implantation in patients with NVG secondary to PDR. Furthermore, the
changes of neurotrophic factors in the vitreous humor before and after anti-VEGF treatment
will be explored.